Quick Takeaways
- Affinity Asset Advisors, LLC filed SCHEDULE 13G/A for Avalo Therapeutics, Inc. Common Stock, par value $0.001 per share (AVTX).
- Disclosed ownership: 7.6%.
- Date of event: 30 Sep 2025.
Affinity Asset Advisors, LLC - 30 Sep 2025 SCHEDULE 13G/A Report for Avalo Therapeutics, Inc. Common Stock, par value $0.001 per share (AVTX)
- Filing Manager
- Affinity Asset Advisors, LLC
- Reporting Manager
- Affinity Healthcare Fund, LP
- Symbol
- AVTX
- Shares outstanding
- 13,153,163 shares
- Disclosed Ownership
- 1,006,217 shares
- Ownership
- 7.6%
- Form type
- SCHEDULE 13G/A
- Filing time
- 13 Nov 2025, 17:21:05 UTC
- Date of event
- 30 Sep 2025
- Previous filing
- 31 Dec 2024
- Next filing
- 29 Jan 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"Affinity Asset Advisors, LLC disclosed 7.6% ownership in Avalo Therapeutics, Inc. Common Stock, par value $0.001 per share (AVTX) on 30 Sep 2025."
What Changed
- Previous schedule filing date: 31 Dec 2024.
- Current filing was accepted on 13 Nov 2025, 17:21.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Affinity Healthcare Fund, LP | 7.6% | 1,006,217 | 0 | 1,006,217 | /s/ Andrew Weinstein | Andrew Weinstein, Chief Financial Officer and Chief Compliance Officer | |
| Affinity Asset Advisors, LLC | 7.6% | 1,006,217 | 0 | 1,006,217 | /s/ Andrew Weinstein | Andrew Weinstein, Chief Financial Officer and Chief Compliance Officer |